Disc Medicine, Inc.

Name: Disc Medicine, Inc. standardized financial statements, quarterly
Creator: Listed

IRONNasdaqCIK 1816736HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$65.1m, Q2 FY2026

Net income−$59.5m, Q2 FY2026

Disc Medicine, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Research and development	$m	14.4	22.6	23.7	23.5	24.7	24.8	27.8	46.3	50.3	46.2	45.9	46.9
Selling, general and administrative	$m	not reported	not reported	7.8	7.4	8.2	9.8	12.2	15.1	17.4	20.7	23.6	18.1
Operating income	$m	(19.0)	(29.7)	(31.5)	(30.9)	(32.9)	(34.6)	(39.9)	(61.4)	(67.7)	(67.0)	(69.5)	(65.1)
Interest expense	$m	not reported	not reported	0.0	0.0	0.0	0.6	0.9	0.9	0.9	0.9	0.8	0.9
Income tax	$m	0.0	0.0	0.0	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.1
Net income	$m	(14.1)	(23.6)	(26.9)	(26.4)	(26.6)	(29.5)	(34.1)	(55.2)	(62.3)	(60.5)	(63.5)	(59.5)
Diluted EPS	$ per share	(0.58)	not reported	(1.09)	(1.03)	(0.89)	not reported	(1.02)	(1.58)	(1.77)	not reported	(1.65)	(1.54)
Basic EPS	$ per share	(0.58)	not reported	(1.09)	(1.03)	(0.89)	not reported	(1.02)	(1.58)	(1.77)	not reported	(1.65)	(1.54)

Balance sheet

Cash and equivalents$98.7m, Q2 FY2026

Long-term debt$59.3m, Q2 FY2026

Shareholders' equity$644.2m, Q2 FY2026

Disc Medicine, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	371	360	343	281	193	192	123	127	141	91.1	88.9	98.7
Current assets	$m	374	366	352	508	493	494	706	662	627	804	747	733
Total assets	$m	376	368	354	510	495	497	709	665	630	807	750	735
Current liabilities	$m	14.4	21.4	14.9	20.3	25.5	23.3	18.7	20.6	26.7	36.6	31.1	30.4
Total liabilities	$m	17.5	22.9	16.1	21.4	27.2	53.2	48.9	50.9	57.1	67.1	61.8	90.9
Long-term debt	$m	not reported	0.0	not reported	not reported	not reported	28.3	28.5	28.7	28.9	29.2	29.4	59.3
Current portion of debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	359	345	338	489	468	444	660	614	573	740	688	644

Cash flow

Operating cash flow−$44.2m, Q2 FY2026

Capital expenditure$0, Q2 FY2026

Disc Medicine, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(7.5)	(17.8)	(33.6)	(15.4)	(17.4)	(27.6)	(41.4)	(47.9)	(47.8)	(43.3)	(62.2)	(44.2)
Capital expenditure	$m	0.0	0.0	0.1	(0.0)	(0.0)	0.4	0.9	0.0	0.0	0.0	0.0	0.0

Diluted shares (weighted)38.69m, Q2 FY2026

Disc Medicine, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	1.0	19.0	21.5	24.3	24.8	25.6	29.9	33.3	35.0	35.2	38.5	38.7

Shares outstanding: 38.39m at Jul 23, 2026, from the cover of the 10-Q filed Jul 30, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. Listed shows no prices and gives no investment advice.